The major strengths of this investigation are the inclusion of a large population of ACS patients and the long-term follow-up. In addition, the study confirms the prognostic value of HRPR for ischemic outcomes and the limited ability of earlier-generation P2Y12 inhibitors to influence HRPR ...
Introduction: Acute coronary syndromes (ACS) are one of the leading causes of death worldwide. Several landmark trials, followed by a widespread introducti... P Adamski,U Adamska,M Ostrowska,... - 《Expert Opinion on Pharmacotherapy》 被引量: 7发表: 2016年 P2Y12 Inhibitors in Acute Coron...
Letter--Prudent Formulary Management or Underutilization of the Novel P2Y12 Receptor Inhibitors in Patients with Acute Coronary Syndrome Who Received Percutaneous Coronary Intervention? DISCLOSURES: The author is a former employee of AstraZeneca and owns stock in AstraZeneca. The author reports no conflic...
The Ca2+ response to VEGF is also sensitive to angiogenesis inhibitors, such as angiostatin and endostatin, which are necessary for vessel pruning and regression of selected vascular branches [12]. Angiostatin comprises of the first four-kringle domains of plasminogen, which is a quite abundant ...
RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook AcronymDefinition DAPTDual Antiplatelet Therapy DAPTDomestic Asset Protection Trust DAPTDiphtheria, Acellular Pertussis, Tetanus(vaccine) DAPTDenver Area Physics Teachers(Denver, CO) ...
New P2Y12 receptor inhibitors (prasugrel and ticagrelor) have clear benefits compared with clopidogrel for dual antiplatelet therapy, and cangrelor or vorapaxar, a thrombin receptor inhibitor, may be of value in specific settings. Anticoagulation uses 1 of 4 choices: bivalirudin, unfractionated heparin,...
The Impact of Preclinical High Potent P2Y 12 Inhibitors on Decision Making at Discharge and Clinical Outcomes in Patients with Acute Coronary Syndrome Background: Purinergic signaling receptor Y12 (P2Y12) inhibitors are a fundamental part of pharmacological therapy in acute coronary syndrome (ACS) for...
With an incidence of 4%, additional therapy to completely prevent IPTE in 100 patients would need to cost $144 to make it cost neutral.Further studies are necessary to determine cost-benefit of therapies to prevent IPTE such as cangrelor or newer P2Y12 inhibitors with more rapid onset.doi:...